Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

5(100.0%)

5Total

N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05551052Active Not Recruiting

CRC Detection Reliable Assessment With Blood

Role: lead

NCT06778317Not Yet Recruiting

MSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients with Cirrhosis

Role: collaborator

NCT03311152Not ApplicableCompleted

Circulating Cell-free DNA-based Epigenetic Biomarker MSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis

Role: collaborator

NCT05614011Not ApplicableCompleted

Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation

Role: collaborator

NCT05584189Not ApplicableCompleted

COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability

Role: collaborator

NCT05584176Not ApplicableCompleted

COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation

Role: collaborator

NCT05555030Not ApplicableCompleted

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

Role: lead

All 7 trials loaded